Oragenics, Inc. (OGEN) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Oragenics, Inc. on December 14, 2021. The report discloses a Regulation FD event involving the company's Executive Chairman, Frederick W. Telling, Ph.D.
Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report is a disclosure of a corporate event rather than a financial statement.
Material Changes
No material financial changes or operational updates are detailed in this specific filing. The document serves solely to disclose the occurrence of a public presentation.
Guidance, Outlook, and Management Commentary
On December 14, 2021, at 1:00 p.m. Eastern time, Executive Chairman Frederick W. Telling participated in a virtual "Fireside Chat" hosted by Alliance Global Partners (AGP). The session was conducted by Matthew Cross, Managing Director of Biotechnology Equity Research at AGP. The company notes that the information provided in the chat is summary in nature and should be considered in the context of other SEC filings and public announcements. The company explicitly states it undertakes no obligation to update or revise the information contained in this report.
Key Facts for Investor Verification
- Verify the content of the Alliance Global Partners "Fireside Chat" by requesting a replay via agpevents@allianceg.com.
- Confirm that the information in this 8-K is not deemed "filed" under Section 18 of the Exchange Act unless specifically incorporated by reference.
- Review subsequent SEC filings or press releases for any updates or clarifications regarding the topics discussed in the chat.
- Note that Michael Sullivan signed the report as Interim Principal Executive Officer and Chief Financial Officer.